Suppr超能文献

在2型糖尿病患者中,二肽基肽酶4浓度受血清胰岛素水平影响,而非动脉僵硬度指数的影响。

Dipeptidyl peptidase 4 concentration influenced by serum insulin levels rather than arterial stiffness index in type 2 diabetics.

作者信息

Wu Liming, Gong Qing, Na Risu, Mao Xudong, Zheng Xulei, Liu Qiaorui, Ma Cong, Ding Xin, Sheng Hongguang, Liu Zhiwen

机构信息

Department of Endocrinology, Xuhui District Central Hospital No. 966, Huaihai Zhong Road, Shanghai 200031, China.

Department of Geriatrics, Xuhui District Central Hospital No. 966, Huaihai Zhong Road, Shanghai 200031, China.

出版信息

Int J Clin Exp Med. 2015 Apr 15;8(4):6236-41. eCollection 2015.

Abstract

OBJECTIVE

To investigate whether inhibitors of dipeptidyl peptidase-4 (DPP-4) can suppress the atherosclerotic development in diabetic patients.

METHODS

The prospective study was carried out in the Out-patient Department of XuHui Central Hospital, Shanghai, China, between March and August 2013. The correlation of major index of glucose and lipid metabolism profiles, and the arterial stiffness index (AI) between diabetic patients and healthy subjects were analyzed.

PATIENTS OR MATERIALS

39 patients with type 2 diabetes and 29 healthy subjects were enrolled for measurements of blood glucose, plasma insulin, HbA1c, TC, cholesterol, HDL, AI and body mass index (BMI).

RESULTS

Significant differences were found between DPP-4 and blood glucose (fasting and 2 h postprandial), HbA1c, cholesterol, high density lipoprotein and arterial stiffness in normal subjects and diabetic patients. Only the fasting insulin concentration and high density lipoprotein had a significant impact on DPP-4 levels.

CONCLUSIONS

It was clear that insulin (fasting) and HDL levels had an impact on DPP-4 activity but only in patients with Type 2 diabetes. The arterial stiffness index was not correlated with DPP-4 levels in Type 2 diabetic patients.

摘要

目的

研究二肽基肽酶-4(DPP-4)抑制剂是否能抑制糖尿病患者动脉粥样硬化的发展。

方法

2013年3月至8月在中国上海徐汇中心医院门诊部进行了一项前瞻性研究。分析了糖尿病患者与健康受试者之间血糖和脂质代谢谱的主要指标以及动脉僵硬度指数(AI)的相关性。

患者或材料

招募了39例2型糖尿病患者和29名健康受试者,测量血糖、血浆胰岛素、糖化血红蛋白(HbA1c)、总胆固醇(TC)、胆固醇、高密度脂蛋白(HDL)、AI和体重指数(BMI)。

结果

正常受试者和糖尿病患者的DPP-4与血糖(空腹和餐后2小时)、HbA1c、胆固醇、高密度脂蛋白和动脉僵硬度之间存在显著差异。只有空腹胰岛素浓度和高密度脂蛋白对DPP-4水平有显著影响。

结论

显然,胰岛素(空腹)和HDL水平对DPP-4活性有影响,但仅在2型糖尿病患者中如此。2型糖尿病患者的动脉僵硬度指数与DPP-4水平无关。

相似文献

5
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.
Diabetologia. 2005 Jun;48(6):1168-72. doi: 10.1007/s00125-005-1749-8. Epub 2005 Apr 29.
9

本文引用的文献

4
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
Atherosclerosis. 2013 Apr;227(2):349-54. doi: 10.1016/j.atherosclerosis.2012.12.018. Epub 2013 Jan 17.
5
DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.
Diabetes Care. 2011 May;34 Suppl 2(Suppl 2):S276-8. doi: 10.2337/dc11-s229.
6
DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes.
Atherosclerosis. 2010 Dec;213(2):429-35. doi: 10.1016/j.atherosclerosis.2010.08.064. Epub 2010 Aug 26.
7
Glucagon-like peptide 1 improved glycemic control in type 1 diabetes.
BMC Endocr Disord. 2003 Apr 10;3(1):3. doi: 10.1186/1472-6823-3-3.
8
Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.
J Clin Endocrinol Metab. 2001 Aug;86(8):3853-60. doi: 10.1210/jcem.86.8.7743.
10
Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
Diabetes. 1995 Jun;44(6):626-30. doi: 10.2337/diab.44.6.626.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验